Key points are not available for this paper at this time.
• Three pyrethroids converge on ovarian-reserve loss with divergent programs. • Phenotype-matched dosing separates compound effects from dose effects. • Type I/II classification does not predict ovarian molecular responses. • CDK4-centered cell-cycle remodeling occurs in compound-specific directions.
Wang et al. (Fri,) studied this question.